UPDATE: In November 2018, South Africa notified the WTO Secretariat that Brazil and India requested to co-sponsor this submission on Promoting Public Health Through Competition Law and Policy. On 29 October 2018, the World Trade Organization (WTO) published a submission… Continue Reading
On Thursday, 20 September 2018, Knowledge Ecology International (KEI) delivered the following statement in Rome during discussions at the WHO Regional Committee for Europe on the WHO Roadmap on Access to Medicines and Vaccines. Oral statement of Knowledge Ecology International… Continue Reading
On Monday morning, 10 September 2018, Knowledge Ecology International (KEI) delivered the following oral statement at the World Health Organization’s (WHO) Informal Discussion of the Roadmap Report on Access to Medicines and Vaccines 2019–2023. The morning session provided UN agencies,… Continue Reading
UPDATE: On Wednesday, 15 August 2018, WHO Director-General, Dr Tedros Adhanom Ghebreyesus provided a response to the open letter on the Roadmap on Access to Medicines and Vaccines 2019-2023. The Director-General’s response can be found here: WHO DG letter to… Continue Reading
In June 2018, the European Union (EU) delivered the following statement on Intellectual Property and the Public Interest at the WTO TRIPS Council. The EU voiced a specific concern over a reference in the WTO submission by China and South… Continue Reading
As reported by Knowledge Ecology International (KEI) in May 2018, “[o]n 25 May 2018, the World Trade Organization (WTO) published a joint submission (IP/C/W/643) by China and South Africa to the TRIPS Council on Promoting Public Health Through Competition Law… Continue Reading
UPDATE: On 29 May 2018, Brazil and India notified the WTO secretariat to be “added to the list of sponsors of the submission circulated in document IP/C/W/643”. (Source: IP/C/W/643/Add.1). On 25 May 2018, the World Trade Organization (WTO) published a… Continue Reading
On April 19, 2018, KEI filed a lawsuit against the National Institutes of Health (NIH) to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences. A copy of… Continue Reading
On Tuesday February 20, 2018, the U.S. Federal Trade Commission approved the Celgene acquisition of Juno, without requiring divestitures. The European Commission did not review the merger. KEI’s February 16, 2018 letter opposing the acquisition is available here. The following… Continue Reading